Search Results

Cell-Easy, a specialized contract development and manufacturing organization in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer.

Catalent, Inc. announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.

Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership

MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announces the launch of a new 600m² production wing at its Belgium site.

Catalent, Inc. (NYSE: CTLT), and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global

Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry and MaSTherCell Global, Inc. (“MaSTherCell Global”), a portfolio company and strategic partner of Great Point, today announce executive promotions at MaSTherCell Global effective January 1, 2019.

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization (CDMO) subsidiary of Orgenesis backed by Great Point Partners and SFPI-FPIM.

Kangstem Biotech today announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD(R).

Great Point Partners, LLC (“Great Point”), a Greenwich- based private investment firm focused on the health care industry, announce today that its portfolio company and strategic partner MaSTherCell Global, Inc. (“MaSTherCell Global”) achieved its first financial milestone targets and as a result Great Point has funded USD 6.6 million of growth equity to the company’s balance sheet.

The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products.